Company Information
Industry 制造业
Company Introduction 公司是一家以国家一类新药金路捷——注射用鼠神经生长因子为龙头产品,以创建一流生物创新药企业为目标的湖北省高新技术生物制药企业,主营业务为生物制品(注射用鼠神经生长因子冻干粉针剂、注射用抗乙肝转移因子冻干粉针剂)、凝血酶和其他化学药品的研发、生产和销售。 公司的核心管理团队结构稳定、风格稳健,有着较高的管理水平。公司汇集了一批高素质的管理人才和专业技术人才,有较强的人才优势。公司严格按照股份制企业规范运作,实行董事会领导下的总经理负责制,采用现代企业管理模式。公司制定了“坚持创新领先、致力持续改进、追求优质高效、满足顾客需求” 的质量方针,建立有完善的质量管理体系,严格按照GMP 要求进行药品生产和全面质量管理。并按照GMP 规范和注册标准制定了一系列完善的生产质量管理程序文件,涵盖了本公司药品生产涉及的研发、采购、仓储、设备设施、生产、检验、质量保证、销售等各个环节的质量管理,整个体系符合新版GMP的管理要求和内容。 公司是湖北省高新技术生物制药企业,具有较强的技术研发实力。2010 年,公司申请并获批了国家博士后科研工作站,先后与华中科技大学、武汉大学等单位合作,联合招收博士后研究人员进站开展研究工作。博士后研究工作的开展,有效带动了公司新药创新项目的研究工作,同时为高层次人才的引进和公司人才梯队的培养起到了很好的带动作用。公司技术中心2017 年被湖北省科技厅认定为“湖北省罕见病药物工程技术研究中心”。
Main Business 生物制品(注射用鼠神经生长因子冻干粉针剂、注射用抗乙肝转移因子冻干粉针剂)、凝血酶和其他化学药品的研发、生产和销售。
Legal Representative 陈亚
Top Executives
董事长:陈亚
董事:杨涛,严洁,朱家凤,夏汉珍,陈煌
独立董事:汪涛,冉明东,周海兵
Top 5 Shareholder
Shareholder name Nature Holding Date
武汉三江源投资发展有限公司流通A股19.26%31/03/2024
武汉伯瑞乐企业管理有限公司流通A股11.30%31/03/2024
陈亚限售股+流通A股8.44%31/03/2024
蒋仕波流通A股2.32%31/03/2024
吴洪新流通A股2.29%31/03/2024
Company Secretary 陈煌
Solicitors 北京市中伦律师事务所
Auditors 中审众环会计师事务所(特殊普通合伙)
Tel No 027-84599931
Fax No 027-84891282
Website www.hiteck.com.cn
Email zhengquanbu@hiteck.com.cn
Company Address
Register: 湖北省武汉经济技术开发区海特科技园
Office: 湖北省武汉经济技术开发区海特科技园
Listing Date 08/08/2017
Shares Capital
Shares Capital: 130,894,391
Total A Share: 130,894,391
Listed A Share: 121,884,641
Non-tradable A Share: 9,009,750
Other Share: 0
Total B Share: 0
Total H Share: 0
EPS(RMB)* ¥ -0.930
DPS(RMB)* --
NBV Per Share(RMB)* ¥ 18.932
Market Capitalization(RMB) 3.165B
Smiley face Only Chinese content is avaliable
N
/
N
 : Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SH-HK Ex-Northbound trade (sell only)
N
/
N
 : Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
* Unadjusted Data
Information provided by: etnet
Terms and Conditions
Risk Disclosure:
The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone.
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.